drugset / Trial / NCT06768944
Subjective Experience Following Psilocybin
RandomizedFactorialQuadruple-blindOther
Summary
The purpose of this study is to determine the importance of the acute subjective experience induced by psilocybin (the primary component of "magic mushrooms") in facilitating positive outcomes. Participants in this study will be given psilocybin in combination with either a placebo or risperidone, an atypical antipsychotic that block the subjective effects of psilocybin.
Timeline
- Start
- 2026-05-15
- Primary completion
- 2027-12
- Completion
- 2028-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Psilocybin | Other / unclassified | — | Oral |
| Subject | Risperidone | Other / unclassified | 1 mg | — |
Indications
No indication recorded.